Physician profile
Fred W Rohm
NPI 1407894926
$5,474.79
in general payments reported to CMS, 2019-2025
40 companies · $592 in 2025
The $592 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,160 · 2020: $1,432 · 2021: $1,756 · 2022: $218 · 2023: $204 · 2024: $112 · 2025: $592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $908.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $907.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $798.06 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $463.42 | 2019-2024 | Farxiga, Airsupra |
| Amarin Pharma, INC. | $411.81 | 2019-2022 | |
| Amgen INC. | $387.32 | 2019-2025 | Evenity |
| Lilly USA, LLC | $342.86 | 2019-2022 | |
| Glaxosmithkline, LLC. | $258.20 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $243.08 | 2019-2022 | |
| Eisai INC. | $229.07 | 2020-2022 | |
| Abbvie INC. | $212.10 | 2020-2025 | Vraylar |
| Pfizer INC. | $180.60 | 2019-2025 | |
| Allergan, INC. | $174.85 | 2019-2021 | |
| Lucid Diagnostics INC. | $156.76 | 2023 | |
| Janssen Pharmaceuticals, INC | $148.49 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $112.47 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.41 | 2019-2021 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fred Rohm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.